All In Biotech

Drug Trial Radar · NCT03939026

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory Large B-Cell Lymphoma or Follicular Lymphoma

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

May 1, 2019

Primary completion

Oct 23, 2021

Study completion Jan 28, 2025

Sponsor

Lead sponsor
Allogene TherapeuticsIndustry
Sponsor type
Industry
First posted
May 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

Conditions

  • Relapsed/Refractory Large B Cell Lymphoma
  • Relapsed/Refractory Follicular Lymphoma

Interventions

  • ALLO-501Genetic

    ALLO-501 is an allogeneic CAR T cell therapy targeting CD19

  • ALLO-647Biological

    ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

  • FludarabineDrug

    Chemotherapy for lymphodepletion

  • CyclophosphamideDrug

    Chemotherapy for lymphodepletion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-501Time frame: 28 days
  2. Proportion of patients experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501Time frame: 33 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Stanford University

    Stanford, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Moffitt Cancer Center

    Tampa, Florida

  • Norton Cancer Institute

    Louisville, Kentucky

  • St. Davids South Austin Medical Center

    Austin, Texas

  • MD Anderson

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.